Indeed, 10% of TCGA-ESCC patients in our analysis are wild type for TP53. Mouse model studies have demonstrated that not all p53 mutations are functionally equivalent, and increasing evidence has shown that certain mutated TP53 products gain additional properties that may result in equally deleterious consequences as functionally null mutants 20. This evidence concerns the gene TP53 and esophageal squamous cell carcinoma.